The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 27 January 2003 doi:10.1084/jem.20021652
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 242K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harte, M. T.
Right arrow Articles by O'Neill, L. A.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harte, M. T.
Right arrow Articles by O'Neill, L. A.J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© Rockefeller University Press, 0022-1007/2003/2/343 $5.00
The Journal of Experimental Medicine, Volume 197, Number 3, 343-351

The Poxvirus Protein A52R Targets Toll-like Receptor Signaling Complexes to Suppress Host Defense

Mary T. Harte1, Ismar R. Haga3, Geraldine Maloney2, Pearl Gray1, Patrick C. Reading3, Nathan W. Bartlett3, Geoffrey L. Smith3, Andrew Bowie2 and Luke A.J. O'Neill1

1 The Cytokine Research Group, Department of Biochemistry, Trinity College, Dublin 2, Ireland
2 The Viral Immune Evasion Group, Department of Biochemistry, Trinity College, Dublin 2, Ireland
3 Department of Virology, The Wright-Fleming Institute, Faculty of Medicine, Imperial College of Science, Technology & Medicine, St. Mary's Campus, London W2 1PG, United Kingdom

Address correspondence to Andrew Bowie, Department of Biochemistry, Trinity College, Dublin 2, Ireland. Phone: 353-1-6082435; Fax: 353-1-6772400; E-mail: agbowie{at}tcd.ie

Toll-like receptors (TLRs) are crucial in the innate immune response to pathogens, in that they recognize and respond to pathogen associated molecular patterns, which leads to activation of intracellular signaling pathways and altered gene expression. Vaccinia virus (VV), the poxvirus used to vaccinate against smallpox, encodes proteins that antagonize important components of host antiviral defense. Here we show that the VV protein A52R blocks the activation of the transcription factor nuclear factor {kappa}B (NF-{kappa}B) by multiple TLRs, including TLR3, a recently identified receptor for viral RNA. A52R associates with both interleukin 1 receptor–associated kinase 2 (IRAK2) and tumor necrosis factor receptor–associated factor 6 (TRAF6), two key proteins important in TLR signal transduction. Further, A52R could disrupt signaling complexes containing these proteins. A virus deletion mutant lacking the A52R gene was attenuated compared with wild-type and revertant controls in a murine intranasal model of infection. This study reveals a novel mechanism used by VV to suppress the host immunity. We demonstrate viral disabling of TLRs, providing further evidence for an important role for this family of receptors in the antiviral response.

Key Words: nuclear factor {kappa}B • signal transduction • vaccinia virus • immunomodulation • Toll-like receptor


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS